Scotia Capital’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
Other funds holding PFE
Scotia Capital's PFE Position: Q2 2026 in Review
Scotia Capital reduced its Pfizer (PFE) stake by 24% in Q2 2026, selling an estimated $6.55M and leaving 808,429 shares worth $19.5M. The position accounts for 0.07% of the portfolio, ranked #152.
Scotia Capital first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $126M in Q4 2021. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Scotia Capital held 808,429 shares of Pfizer worth $19.5M as of Q2 2026.
- Scotia Capital sold 250,397 Pfizer shares in Q2 2026, an estimated $6.55M.
- Pfizer made up 0.07% of Scotia Capital's portfolio in Q2 2026, its #152 holding.
- Scotia Capital first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
- Scotia Capital's Pfizer position peaked at $126M in Q4 2021.
- 2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Scotia Capital's 13F filing for Q2 2026, filed 11 Aug 2026.